SCHEMBL13796942

SCHEMBL13796942

O=S(=O)(NC[C@H]1CC[C@H](CNc2nc(NCC3CC3)c3ccccc3n2)CC1)c1ccccc1C(F)(F)F

nearest known ligand 0.60

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ NPY5R Q15761 14/20 0.60
▸ ADRA2A P08913 6/20 0.60
▸ MCHR1 Q99705 5/20 0.60
▸ NPY1R P25929 3/20 0.60
▸ AQP1 P29972 2/20 0.60
▸ ALDH1A1 P00352 1/20 0.60
▸ MAPT P10636 1/20 0.60
▸ HPGD P15428 1/20 0.60
▸ NPY2R P49146 1/20 0.60
▸ NPY4R P50391 1/20 0.60
▸ TDP1 Q9NUW8 1/20 0.60
▸ TLR7 Q9NYK1 1/20 0.55
▸ SLC6A4 P31645 2/20 0.51
▸ CNR2 P34972 3/20 0.50
▸ CNR1 P21554 1/20 0.50
▸ SOS1 Q07889 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13796530 0.93 NPY5R (0.57) NPY5RADRA2AMCHR1NPY1RAQP1
SCHEMBL13796988 0.93 NPY5R (0.59) NPY5RADRA2AMCHR1NPY1RAQP1
SCHEMBL13796975 0.93 NPY5R (0.57) NPY5RADRA2AMCHR1NPY1RAQP1
SCHEMBL14606897 0.93 NPY5R (0.56) NPY5RADRA2AMCHR1NPY1RAQP1
SCHEMBL13796919 0.93 NPY5R (0.56) NPY5RADRA2AMCHR1NPY1RAQP1
SCHEMBL13796626 0.93 NPY5R (0.56) NPY5RADRA2AMCHR1NPY1RAQP1
SCHEMBL13795804 0.91 NPY5R (0.54) NPY5RADRA2AMCHR1NPY1RAQP1
SCHEMBL13797014 0.90 NPY5R (0.54) NPY5RADRA2AMCHR1NPY1RAQP1
SCHEMBL8898897 0.89 NPY5R (0.75) NPY5RADRA2AMCHR1NPY1RAQP1
SCHEMBL13795829 0.87 NPY5R (0.63) NPY5RADRA2AMCHR1NPY1RAQP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7544690-B2 MCH receptor antagonists TAISHO PHARMACEUTICAL CO., LTD. (JP) 2009-06-09 — — US disclosed
US-7544690-B2 MCH receptor antagonists TAISHO PHARMACEUTICAL CO., LTD. (JP) 2009-06-09 — — US disclosed
US-20070037836-A1 Melanin concentrating hormone; obesity and related disorders, anxiety, or depression; trans-4-Bromo-N-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-2-trifluoromethoxy-benzenesulfonamide TAISHO PHARMACEUTICAL CO., LTD. (JP) 2007-02-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070037836-A1 Melanin concentrating hormone; obesity and related disorders, anxiety, or depression; trans-4-Bromo-N-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-2-trifluoromethoxy-benzenesulfonamide MCHR1, MCHR2, MC4R NPY5R 11/4885ADRA2A 131/4885MCHR1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback